F Stock DD Ford Motor Co. 08/27/2014 17:48:20

New Post Public Reply Private Reply Replies (0) Message Board

Aug 27, 2014 at 6:48 PM

F Ford Motor Co. $F Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=F&ty...mp;yt0=Go!

Last Updated: 08/27/2014 17:48:14

Current Price and Quotes
Last Price 17.36
Previous Close 17.19 Open 17.23
Daily Range 17.21 - 17.40 52wk Range 14.40 - 18.12
Volume 18,022,888 Dividend 0.50
Average Vol (30d) 25,619,749 Yield 2.88

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 146,917,000 133,559,000 135,605,000 128,954,000
Cost of Revenue 128,094,000 116,107,000 117,225,000 104,451,000
Gross Profit 18,823,000 17,452,000 18,380,000 24,503,000
Operating Expenses

Research and Development - - - -
Sales, General and Admin. 13,176,000 11,494,000 10,884,000 16,254,000
Non-Recurring Items 208,000 77,000 (36,000) (216,000)
Other - - - -
Operating Income 5,439,000 5,881,000 7,532,000 8,465,000
Income From Continuing Operations

Add'l Income/Expense Items 1,322,000 1,964,000 1,466,000 (47,000)
Earnings Before Interest and Tax 7,830,000 8,433,000 9,498,000 8,956,000
Interest Expense 829,000 713,000 817,000 1,807,000
Earnings Before Tax 7,001,000 7,720,000 8,681,000 7,149,000
Income Tax (147,000) 2,056,000 (11,541,000) 592,000
Minority Interest (7,000) (1,000) 9,000 (4,000)
Equity Earnings Unconsolidated Subsidiary 1,069,000 588,000 500,000 538,000
Net Income Cont. Operations 8,224,000 6,253,000 20,713,000 7,099,000
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 7,155,000 5,665,000 20,213,000 6,561,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 7,155,000 5,665,000 20,213,000 6,561,000

Recent News

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Sinclair Faces Labor Lawsuit for Break-time Violations

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Ping An's Bold Green Moves Ahead of APEC 2026

By Owen Jenkins Updated Oct 25, 2026 Category News Views 175

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Love Business Group Helps SMEs Navigate Broadband Choices

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...